| TBC |
Afamelanotide for erythropoietic protoporphyria [ID927] |
15 May 2023 |
| TA721 |
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] |
3 September 2020 |
| TBC |
Afamelanotide for treating erythropoietic protoporphyria |
30 July 2018 |
| TA111 |
Alzheimer´s disease - donepezil, rivastigmine, galantamine and memantine (review) |
13-14 August 2006 |
| TA142 |
Anaemia (cancer-treatment induced) - Erythropoetin (alpha and beta) and darbepoetin |
2 June 2006 |
| TA143 |
Ankylosing spondylitis - adalimumab, etanercept & infliximab |
31 March 2008 |
| TA010 |
Asthma (children under 5) - inhaler devices |
31 August 2000 |
| TA138 |
Asthma (in adults) - corticosteroids |
9 January 2008 |
| TA038 |
Asthma (older children) - inhaler devices |
13 February 2002 |
| TA249 |
Atrial fibrillation - dabigatran etexilate |
7 February 2012 |
| TA098 |
Attention deficit hyperactivity disorder - Methylphenidate, atomoxetine and dexamfetamine (review) |
25 September 2005 |
| ID3735 |
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy |
28 September 2021 |
| TA926 |
Baricitinib for treating severe alopecia areata |
12 September 2023 |
| TA006 |
Breast cancer - taxanes |
3 May 2000 |
| TA054 |
Breast cancer - vinorelbine |
15 August 2002 |
| TBC |
Breast cancer (advanced or metastatic) - lapatinib |
8 June 2009 |
| TBC |
Breast cancer (advanced or metastatic) - lapatinib (second appeal) |
17 August 2010 |
| TA107 |
Breast cancer (early) - trastuzumab |
26 July 2006 |
| TA257 |
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal |
23 May 2011 |
| TA006 |
Breast cancer - taxanes |
14 June 2000 |
| TA250 |
Breast cancer - eribulin |
13 February 2012 |
| TA350 |
Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane) |
13 October 2014 |
| TA928 |
Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine |
19 September 2023 |
| TA033 |
Colorectal cancer - Irinotecan, oxaliplatin and raltitrexed |
23 May 2001 |
| TA033 |
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed |
8 January 2002 |
| TA307 |
Colorectal cancer (metastatic) – aflibercept |
23 January 2014 |
| TA118 |
Colorectal cancer (metastatic) - bevacizumab & cetuximab |
27 November 2006 |
| TA102 |
Conduct disorder in children - parent-training/education programmes |
21 April 2006 |
| TA152 |
Coronary artery stents - drug-eluting stents |
14 April 2008 |
| TA051 |
Depression and anxiety - computerised cognitive behaviour therapy (CCBT) |
19 July 2002 |
| TA097 |
Depression and anxiety - computerised cognitive behavioural therapy (CCBT)(review) |
17 November 2005 |
| TA151 (review TA57) |
Diabetes - insulin pump therapy (review) |
16 May 2008 |
| TA063 |
Diabetes (Type 2) - glitazones (review) |
2 June 2003 |
| TA459 |
Dupuytren's contracture - collagenase clostridium histolyticum |
30 November 2015 |
| TA007 |
Dyspepsia - proton pump inhibitors |
29 June 2000 |
| TA059 |
Electroconvulsive Therapy (ECT) |
12 February 2003 |
| TA076 |
Epilepsy (adults) - newer drugs |
19 January 2004 |
| TBC |
Erenumab for treating migraine |
4 December 2019 |
| TA854 |
Esketamine for treatment-resistant depression [ID1414] |
27 July 2022 |
| TA067 |
Flu (prophylaxis) - amantadine and oseltamivir |
19 December 2002 |
| TA759 |
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087] |
9 November 2021 |
| TA064 |
Growth hormone deficiency (adults) - human growth hormone |
20 August 2002 |
| TA064 |
Growth hormone deficiency (adults) - human growth hormone |
3 July 2003 |
| TA145 |
Head and neck cancer - cetuximab |
22 August 2007 |
| TA008 |
Hearing disability - hearing aids |
21 July 2000 |
| TA166 |
Hearing impairment - cochlear implants |
26 November 2008 |
| TA189 |
Hepatocellular carcinoma (advanced and metastatic)- sorafenib |
26 February 2010 |
| TA018 |
Hernia (inguinal) - laparoscopic surgery |
7 December 2000 |
| TA002 |
Hip disease - replacement prostheses |
31 March 2000 |
| TA164 |
Hyperuricaemia - febuxostat |
29 October 2008 |
| TA504 |
Idiopathic pulmonary fibrosis - pirfenidone |
2 December 2016,
and 1 December 2017 |
| TA501 |
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer |
8 December 2017 |
| TA482 |
Kidney transplantation (adults) - immunosuppressive therapy (review) |
30 March 2016 |
| TA482 |
Kidney transplantation (children, adolescents) - immunosuppressive regimens (review) |
30 March 2016 |
| TA541 |
Leukaemia (acute lymphoblastic, relapsed, adults) - inotuzumab ozogamicen |
3 November 2017 |
| TA193 |
Leukaemia (chronic lymphocytic, relapsed) - rituximab |
25 May 2010 |
| TA251 |
Leukaemia (chronic myeloid) - dastatinib, nilotinib, imatinib (intolerant, resistant) (including partial review of TA70) |
4 November 2011 |
| TA162 |
Lung cancer (non-small cell) - Erlotonib |
6 June 2007 |
| TA227 |
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib: appeal |
16 May 2011 |
| TA124 |
Lung cancer (non-small cell) - pemetrexed |
6 June 2007 |
| TBC |
Lysosomal acid lipase deficiency - sebelipase alfa |
25 April 2017 |
| TA068 |
Macular degeneration (age-related) - photodynamic therapy |
17 March 2003 |
| TA155 |
Macular degeneration (age-related) - ranibizumab and pegaptanib |
30 June 2008 |
| TA237 |
Macular oedema (diabetic) - ranibizumab: appeal |
4 October 2011 |
| TA078 |
Menorrhagia - endometrial ablation |
26 January 2004 |
| TA135 |
Mesothelioma - Pemetrexed disodium |
27 October 2006 |
| TA754 |
Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405] |
11 May 2021 |
| TA020 |
Motor neurone disease - riluzole |
4 January 2001 |
| TA129 |
Multiple myeloma - Bortezomib |
8 February 2007 |
| TA228 |
Multiple myeloma (first line) - bortezomib and thalidomide |
15 November 2010 |
| TA032 |
Multiple sclerosis - beta interferon and glatiramer |
22-23 September 2000 |
| TA032 |
Multiple sclerosis - beta interferon and glatiramer acetate |
26 November 2001 |
| TA218 |
Myelodysplastic syndrome - azacitidine |
1 June 2010 |
| TBC |
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) |
30 September 2016 |
| TA494 |
Obesity (prolonged-release) - naltrexone-bupropion |
12 December 2017 |
| ID3913 |
Olipudase alfa for treating Niemann-Pick disease types A and B |
24 May 2024 |
| TA621 |
Osimertinib for untreated EGFR-positive non-small-cell lung cancer |
30 September 2019 |
| TA027 |
Osteoarthritis and rheumatoid arthritis - cox II inhibitors |
7 June 2001 |
| TA160 |
Osteoporosis - primary prevention |
22 October 2007 |
| TA160 |
Osteoporosis - primary prevention |
15 September 2008 |
| TA087 |
Osteoporosis - secondary prevention |
22 October 2004 |
| TA161 |
Osteoporosis - secondary prevention including strontium ranelate |
22 October 2007 |
| TA161 |
Osteoporosis - secondary prevention including strontium ranelate |
15 September 2008 |
| TA055 |
Ovarian cancer - paclitaxel (review) |
12 November 2002 |
| TA389 |
Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468] |
24 April 2015 |
| TA360 |
Pancreatic adenocarcinoma (Metastatic) paclitaxel albumin-bound nanoparticles (with gemcitabine, 1st line) [ID680] |
16 March 2015 |
| TBC |
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536] |
23 June 2020 |
| TA135 |
Pemetrexed disodium for the treatment of malignant pleural mesothelioma (2) |
23 November 2007 |
| TA103 |
Psoriasis - efalizumab and etanercept |
27 January 2006 |
| TA104 |
Psoriatic arthritis - etanercept and infliximab |
20 February 2006 |
| TA104 |
Psoriatic arthritis (active) - apremilast (after-DMARDs) |
6 November 2015 |
| TA255 |
Prostate cancer - cabazitaxel |
22 March 2012 |
| TA352 |
Prostate cancer (advanced, hormone dependent) - degarelix depot [ID590] |
12 November 2014 |
| TA832 |
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids [ID3842] |
7 September 2022 |
| TA178 |
Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus |
13 July 2009 |
| TA333 |
Renal cell carcinoma, locally advanced and/or metastatic (2nd line) - axitinib [ID518] |
10 June 2013 |
| TA219 |
Renal cell carcinoma (second line metastatic) - everolimus |
28 February 2011 |
| TA085 |
Renal transplantation - immuno-suppressive regimens (adults) |
26 April 2004 |
| TA130 |
Rheumatoid arthritis - Adalimumab, etanercept and infliximab |
4 April 2007 |
| TA072 |
Rheumatoid arthritis - anakinra |
18 September 2003 |
| TA375 |
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537] |
26 November 2015 |
| TA141 |
Rheumatoid arthritis (refractory) - abatacept |
17 March 2008 |
| TA037 |
Rituximab for follicular lymphoma |
21 May 2001 |
| TA043 |
Schizophrenia - Atypical antipsychotic |
24 April 2002 |
| TA397 |
Systemic lupus erythematosus (active) - belimumab |
18 July 2012 |
| TA696 |
Tafamidis for treating transthyretin amyloid cardiomyopathy |
4-5 March 2021 |
| TBC |
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795] |
14 November 2022 |
| TA272 |
Transitional cell carcinoma of the urothelial tract - vinflunine |
23 May 2011 |
| TA090 |
Vascular disease - clopidogrel and dipyridamole |
25 February 2005 |